Archives

  • 2022-08
  • 2022-07
  • 2022-05
  • 2022-04
  • 2021-03
  • 2020-08
  • 2020-07
  • 2018-07
  • Statistical analysis br ACCEPTED MANUSCRIPT br Continuous variables were described

    2022-05-25

    Statistical analysis
    ACCEPTED MANUSCRIPT
    Continuous variables were described as the mean ± standard deviation (SD) for normally distributed variables or the median for variables with a skewed distribution. Categorical variables were described as percentages. Comparisons among groups were conducted with unpaired or paired two-tailed t-tests or ANOVA for means if the data were normally distributed or with Wilcoxon’s rank-sum tests if the data were not normally distributed. The test of categorical variables was the row by column chi-square test. All statistical methods were performed using SPSS 20.0 version (IBM Inc., Chicago Illinois, USA, 2011) and GraphPad Prism 5.04 software (GraphPad Software, Inc., San Diego, California). Unless otherwise specified, P < 0.05 was considered statistically significant.
    Results Baseline features of patients in each group
    In total, 240 patients were included. Among them, 234 (97.5%) were males, 235 (97.9%) patients with non-small cell lung cancer (NSCLC) and 6 (2.1%) patients with small cell lung cancer (SCLC). The patients’ ages ranged from 36 to 80 years old, and their mean ages were 61 years old. The median nicotine tolerance score in the failure of the smoking cessation group was 2. Eighty-six were never smokers, 51 failed to quit smoking, and 104 successfully quit smoking. There was no significant difference in gender composition, occupation, educational level, marital status or household income among the three groups (Table 1). Smoking status in the failure to quit smoking and success group
    The smoking duration of the failure to quit smoking group was 43 years, which was significantly higher than that Cyclophosphamide of the successful smoking cessation group (33 years; P < 0.001). The start smoking age in the failure to quit smoking group was significantly younger than that in the successful smoking cessation group (18 vs. 21 years old; P = 0.001; Figure 1).
    Relationship between different genotypes of CHRNA5, CHRNA3, CHRNA4 and smoking cessation
    There was Cyclophosphamide no significant difference in the distribution of GG, AG and AA genotypes among the three groups of patients (P = 0.388; Table 2). There was no significant difference in the genotype distribution of CHRNA5 (rs588765) among the three groups (P = 0.277; Table 2). There was a significant difference in the GG and AG and AA genotype distribution of CHRNA3 rs578776 among the three groups (P = 0.003), and GG (upper left FAM) had the highest proportion (23.1%) in the success of the smoking cessation group (Table 2). These results indicated that patients with the GG genotype in CHRNA3 rs578776 were more likely to successfully quit smoking. There was a significant difference in the distribution of CHRNA4 rs1044396 genotypes among the three groups of patients (P = 0.001; Table 2). The AA genotype (lower right VIC) of CHRNA4 rs1044396 only appeared in the successful smoking cessation group (7.7%), indicating that patients with this genotype were more likely to quit smoking. There was a significant difference in the distribution of CHRNA4 rs2229959 genotypes among the three groups (P = 0.003; Table 2). The CC genotype (upper left FAM) in the group that quit smoking and never smokers accounted for 8.7% and 1.2%, respectively. However, it did not appear in the failure to quit smoking group, indicating that patients with the CC genotype in rs2229959 were more likely to successfully quit smoking. There was no significant difference in the genotype distribution of CHRNA4 rs2236196 5
    ACCEPTED MANUSCRIPT
    Discussion
    In this study, we found that patients with lung cancer in the failure to quit smoking group had a significantly higher smoking duration and younger initial smoking age than those in the successful smoking cessation group. Moreover, we first reported that patients with the GG genotype in CHRNA3 (rs578776), the AA genotype in CHRNA4 (rs1044396) and the CC genotype in CHRNA4 (rs2229959) were more likely to quit smoking successfully.